The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. - Wikidata - awgldk - TriplyDB

The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.

The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.

http://www.wikidata.org/entity/Q41337231

about

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers.Emtricitabine + tenofovir alafenamide for the treatment of HIV.Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients.Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy.Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed.Metabolic Effects of Pre-Exposure Prophylaxis with Co-Formulated Tenofovir Disoproxal Fumarate and Emtricitabine.A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.AIDS Clinical Research in Spain-Large HIV Population, Geniality of Doctors, and Missing Opportunities.

P2860

Q28553066-218C0381-7FED-4D5D-AB7D-1A7102C1620A Q33669829-32AC356C-FA04-4CEE-9425-9FEC918F9C94 Q37582471-B3CC43E6-9501-4AD2-AEA5-0BA6DFFF86ED Q37604553-3E5E0E3B-A5DC-4D10-96A3-55B14F20BCFD Q38679618-84ECFBC8-DE15-4634-8ED1-5A60A9C29735 Q38984695-E5E87550-90F7-448D-A38D-6C509AC11423 Q39015984-9B78194C-A42F-4314-8A24-E236B0E27B85 Q40229714-330B5C20-CC99-41CC-A235-48F1A36FB782 Q40374341-535F3D9C-7B48-4BD3-80C9-C3C5FAE5734D Q48355843-EEAB6846-4816-4802-9D9F-F0898262F353 Q50132896-2407C488-F32E-4D07-8D1D-D5CEF5530FC9 Q54211761-230A4BC1-14B8-4E2E-91B0-CA1248603B70 Q55698444-7B773FA3-DF6D-4801-901D-0A90E04C39C0

P2860

The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.

http://www.wikidata.org/entity/Q41337231

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The lipid-lowering effect of t ...... ind, placebo-controlled trial.

@en

type

label

The lipid-lowering effect of t ...... ind, placebo-controlled trial.

@en

prefLabel

The lipid-lowering effect of t ...... ind, placebo-controlled trial.

@en

P1433

Q41337231-0C296A84-D1F4-474A-9EC1-8E0CD6782D9B

P1476

Q41337231-A3BFC584-9131-40FB-A6FE-3CCA4BC224CF

P2093

Q41337231-304E2829-5233-4952-B9B2-BCA706C43278

Q41337231-508332E6-1C71-4777-ADDC-072FD550FAB9

Q41337231-56B8208B-BFAC-4C2E-B6DD-CE33346F0143

Q41337231-8237C850-5D51-4CF2-8FFF-30F67E594229

Q41337231-A1B4B48E-924A-4B15-8F2A-11BC2FDC1035

Q41337231-BE5B9DF0-E00F-454F-97A4-8A2B11DE98E9

Q41337231-C0CB93A0-96E5-44C5-9FD1-2D8CF1A7602B

Q41337231-C25AA7C9-E747-4A7F-AE2C-CAFDF222C7D8

Q41337231-C4FEA7EB-8C4C-4410-B4FC-49C25219BB7E

P2860

Q41337231-053CFD73-76CB-4C62-A5C0-F4B50CB93D7E

Q41337231-0BAD6FBB-8C9F-4DE3-9D12-201BECBD6ECE

Q41337231-2C2747CE-B2E2-40BD-8833-13FDA1647F41

Q41337231-34A64B2A-1435-46D1-AB26-F6F1DBFED42F

Q41337231-38164E58-0A59-446D-8FF3-37A35EF0C7BC

Q41337231-48493F27-614A-401E-A498-5A1F379A451E

Q41337231-49220B6F-162C-47C5-B239-A8DA305992AA

Q41337231-4CBF7D9D-69A5-4242-9D81-171CDADC4ECF

Q41337231-502BE661-4642-4015-A9BF-90A3A3EB999A

Q41337231-62B0DF0A-8F39-4FB5-93EB-B6DCBB635C45

P304

Q41337231-B21E773D-EBB2-44D4-BD19-E50EA37BF3DD

P31

Q41337231-A2B3C72D-CA5A-455E-8E0A-BB5192913A37

P356

Q41337231-C25BE49A-EB16-4C42-83D6-8208369ABE80

P407

Q41337231-2575A988-7984-4448-8619-6B24536FDCB8

P433

Q41337231-5952DE2B-D51A-415F-A210-25D7091E899F

P478

Q41337231-2655677A-D104-49E8-8FA7-79976931BDAE

P50

Q41337231-099FA05F-D0BE-4C4E-929A-D5F7CC3BD479

Q41337231-14823D0C-3D94-47D2-9E43-8188E28127ED

Q41337231-262A69EA-0699-4BE1-A35F-F2F5D5D331DE

Q41337231-37A6DD2E-BD23-4795-85A5-791C853CC553

Q41337231-6EE42660-04E4-4B1A-A414-85A7782DDB8F

Q41337231-9BB0659F-1D7B-4B24-87EF-606286D5B873

P577

Q41337231-02C2063C-4F4B-4A66-8F78-FD60D1C5A16E

P698

Q41337231-427EF677-3751-4322-B9CC-943FD7008FAB

P921

Q41337231-55C17083-CA78-4F14-8C76-B0EAE1AAD33D

P356

P1433

Clinical Infectious Diseases

P1476

The lipid-lowering effect of t ...... ind, placebo-controlled trial.

@en

P2093

Carla Estany

http://www.w3.org/2001/XMLSchema#string

Daniel Podzamczer

http://www.w3.org/2001/XMLSchema#string

Eugènia Negredo

http://www.w3.org/2001/XMLSchema#string

Isabel Bravo

http://www.w3.org/2001/XMLSchema#string

Josep M Llibre

http://www.w3.org/2001/XMLSchema#string

José R Santos

http://www.w3.org/2001/XMLSchema#string

María Saumoy

http://www.w3.org/2001/XMLSchema#string

Roger Paredes

http://www.w3.org/2001/XMLSchema#string

Tenofovir/emtricitabine inflUence on LIPid metabolism (TULIP) Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

Emtricitabine: a review of its use in the management of HIV infection.

Association of tenofovir exposure with kidney disease risk in HIV infection.

Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.

Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?

P304

403-408

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIV296

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Bonaventura Clotet Sala

Eugènia Negredo

Daniel Podzamczer

P577

2015-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25870325

http://www.w3.org/2001/XMLSchema#string

P921